Brokerages predict that Kadmon Holdings, Inc. (NYSE:KDMN) will post sales of $4.07 million for the current quarter, according to Zacks. Two analysts have made estimates for Kadmon’s earnings, with estimates ranging from $3.00 million to $5.13 million. Kadmon posted sales of $4.28 million during the same quarter last year, which would indicate a negative year over year growth rate of 4.9%. The company is expected to report its next earnings report on Wednesday, March 28th.

On average, analysts expect that Kadmon will report full year sales of $4.07 million for the current financial year, with estimates ranging from $13.50 million to $15.73 million. For the next financial year, analysts expect that the business will report sales of $13.68 million per share, with estimates ranging from $4.65 million to $18.90 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Kadmon.

Kadmon (NYSE:KDMN) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The company had revenue of $2.28 million during the quarter, compared to analysts’ expectations of $5.69 million. The firm’s quarterly revenue was down 60.0% compared to the same quarter last year. During the same period last year, the business earned ($4.24) earnings per share.

KDMN has been the subject of several research analyst reports. Zacks Investment Research raised Kadmon from a “sell” rating to a “hold” rating in a report on Tuesday, November 21st. WBB Securities downgraded Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price objective for the company. in a report on Monday, October 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a report on Friday, November 17th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Kadmon has a consensus rating of “Hold” and a consensus target price of $9.75.

Several institutional investors have recently added to or reduced their stakes in KDMN. Renaissance Technologies LLC purchased a new stake in shares of Kadmon during the first quarter worth approximately $158,000. Sawtooth Solutions LLC raised its stake in shares of Kadmon by 396.9% during the second quarter. Sawtooth Solutions LLC now owns 99,649 shares of the company’s stock worth $388,000 after purchasing an additional 79,593 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Kadmon by 17.0% during the second quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Kadmon by 166.0% during the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock worth $5,870,000 after purchasing an additional 941,549 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Kadmon during the second quarter worth approximately $114,000. Institutional investors and hedge funds own 51.90% of the company’s stock.

Kadmon (NYSE KDMN) traded up $0.13 during mid-day trading on Monday, hitting $3.64. The stock had a trading volume of 383,200 shares, compared to its average volume of 286,519. Kadmon has a 1-year low of $2.05 and a 1-year high of $5.93.

TRADEMARK VIOLATION NOTICE: This article was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/zacks-analysts-expect-kadmon-holdings-inc-kdmn-will-post-quarterly-sales-of-4-07-million/1757514.html.

About Kadmon

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.